The Danish biopharmaceutical manufacturer DanCann Pharma has just announced that the first phase in the establishment of the company's high-tech production Facility, the BIOTECH PHARM1, in Ansager has now been completed - and that the Facility has been put into operation. The Facility is built on the basis of best practices from the pharmaceutical industry in combination with advanced environmentally controlled agricultural technology and vertical agriculture. BIOTECH PHARM1 is designed to supply cannabis bulk to the global market in accordance with EU Good Manufacturing Practice (GMP) standards and is also prepared for future biopharmaceutical downstream production. The Facility contains, among other things, a department with a fully automatic vertical cultivation system as well as departments for washing, finishing, inspection, storage, and shipping.
"I am incredibly proud to announce that the construction and commissioning of BIOTECH PHARM1 is now in place. It is an important milestone for the Company and an achievement that has required a huge commitment and lots of patience from both colleagues, forces in the local area, partners, contractors, and investors. I would like to thank everyone who has been involved in this extraordinary project, "says Morten Martinsen, who is COO at DanCann Pharma and co-establish the Company as one of the first ones together with CEO, Jeppe Krog Rasmussen, in 2018.
BIOTECH PHARM1 can copy and control microclimatic conditions very closely and accurately without interference from external environmental factors. This provides complete and specific control over all cultivation cells in the Facility and makes it possible to mimic different climates from around the world completely uniquely if necessary, in relation to the specific plant genetics. This level of control and precision ensures consistent results, yield, and product safety from batch to batch.
The first, carefully selected, genetic biomaterial has already been successfully established in BIOTECH PHARM1, and the first training harvest will take place in the coming months.
"DanCann Pharma's cannabis genetics respond extremely well to the unique growth conditions and practices found in the Facility. These genetics will be the basis of the entire Facility and will ultimately help improve the quality of life for the many patients with challenges. I look forward to our next step and the process around the GMP-certification, so that we can start our exports and meet global demand in the coming year,” says Morten Martinsen.
For more information:
Dancann Pharma
www.dancann.com